New Hampshire
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
No racial disparities were found in New Hampshire for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in New Hampshire is 58.6 and significantly higher than the national rate of 52.1.
- It ranks 36th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in New Hampshire improved by 12%.
- Note: When examining incidence data, it is important to note that the COVID-19 pandemic disrupted access to medical care. This resulted in a drop in cancer diagnoses for the year 2020, particularly for cancers diagnosed before symptoms develop (including lung cancer). This drop reflects changes in medical care for 2020 and should not necessarily be interpreted as a reduction in the underlying cancer burden.
Five-Year Survival Rate:
- The percent of people living five years after being diagnosed with lung cancer (the survival rate) in New Hampshire is 33.6%, which is significantly higher than the national rate of 31.0%.
- It ranks 9th among the 43 states with survival data, placing it in the above average tier.
- Over the last five years, the survival rate in New Hampshire improved by 25%.
Early Diagnosis:
- In New Hampshire, 33.1% of cases are caught at an early stage, which is significantly higher than the national rate of 29.3%.
- It ranks 8th among the 47 states with data on diagnosis at an early stage, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in New Hampshire improved by 27%.
Lung Cancer Treatment
Biomarker Coverage:
- New Hampshire has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2026.
Surgical Treatment:
- New Hampshire ranked 7th (out of the 40 states with available data) with 24.5% of cases undergoing surgery as part of the first course of treatment.
- This is significantly higher than the national rate of 21.4% and puts New Hampshire in the above average tier.
No Treatment:
- New Hampshire ranked 11th (out of the 47 states with available data) with 17.5% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.9% and puts New Hampshire in the above average tier.
Screening
Screening for High Risk:
- In New Hampshire, 33.1% of those at high risk were screened, which was significantly higher than the national rate of 24.4%.
- It ranks 4th (out of the 50 states with available data), placing it in the top tier.
Prevention
Tobacco Use:
- The 2025 smoking rate in New Hampshire is 8.2% and significantly lower than the national rate of 10.4%.
- It ranks 6th (out of the 48 states with available data), placing it in the above average tier.
Radon:
- In New Hampshire, 35.3% of radon tests results were at or above the action level recommended by EPA.
- It ranks 36th among all states, placing it in the below average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 41.8 per 100,000 population among Black individuals in New Hampshire, not significantly different than the rate of 53.5 among Black individuals nationally, and not significantly different than the rate of 59.5 among white individuals in New Hampshire.
- The five-year survival rate is 36.3% among Black individuals in New Hampshire, not significantly different than the rate of 28.5% among Black individuals nationally, and not significantly different than the rate of 33.7% among white individuals in New Hampshire.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Black individuals in New Hampshire due to data limitations.
Latino individuals:
- The rate of new lung cancer cases is 44.7 per 100,000 population among Latino individuals in New Hampshire, significantly higher than the rate of 27.8 among Latino individuals nationally, and significantly lower than the rate of 59.5 among white individuals in New Hampshire.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Latino individuals in New Hampshire due to data limitations.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 21.7 per 100,000 population among Asian or Pacific Islanders individuals in New Hampshire, significantly lower than the rate of 32.7 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 59.5 among white individuals in New Hampshire.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Asian or Pacific Islander individuals in New Hampshire due to data limitations.
Indigenous Peoples:
- Lung cancer data (including rates, early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Indigenous Peoples (American Indians/Alaska Natives) in New Hampshire due to data limitations.
Summary
Despite the early diagnosis rate in New Hampshire falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
New Hampshire has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
New Hampshire falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 10, 2026